Who are Rapaflo's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Uroxatral, Coreg, Cardura, Dapiprazole Hydrochloride, Hytrin, Minipress.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/silodosin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Rapaflo — Competitive Intelligence Brief

Rapaflo (SILODOSIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alpha-Adrenergic Blocker [EPC]. Area: Urology.

marketed alpha-Adrenergic Blocker [EPC] alpha-1 adrenoreceptors Urology Small molecule Live · refreshed every 30 min

Target snapshot

Rapaflo (SILODOSIN) — AbbVie. Silodosin blocks alpha-1 adrenoreceptors in the prostate and bladder, causing smooth muscle relaxation and improving urine flow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rapaflo TARGET	SILODOSIN	AbbVie	marketed	alpha-Adrenergic Blocker [EPC]	alpha-1 adrenoreceptors	2008-01-01
Uroxatral	ALFUZOSIN	Advanz	marketed	alpha-Adrenergic Blocker	alpha 1-adrenoreceptors	2003-01-01
Coreg	CARVEDILOL	Waylis	marketed	alpha-Adrenergic Blocker [EPC]	Beta-2 adrenergic receptor	1995-01-01
Cardura	DOXAZOSIN	Viatris	marketed	alpha-Adrenergic Blocker	Alpha-1B adrenergic receptor	1990-01-01
Dapiprazole Hydrochloride	DAPIPRAZOLE	Fera Pharms	marketed	alpha-Adrenergic Blocker	Alpha-1D adrenergic receptor	1990-01-01
Hytrin	TERAZOSIN		marketed	alpha-Adrenergic Blocker	Alpha-1D adrenergic receptor	1987-01-01
Minipress	PRAZOSIN	Pfizer	marketed	alpha-Adrenergic Blocker	Alpha-1A adrenergic receptor	1976-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (alpha-Adrenergic Blocker [EPC] class)

AbbVie · 1 drug in this class
Waylis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rapaflo — Competitive Intelligence Brief. https://druglandscape.com/ci/silodosin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab